Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy.
作者： J P O'Connell , M G Kris , R J Gralla , S Groshen , A Trust
DOI: 10.1200/JCO.1986.4.11.1604
关键词:
摘要: To determine the frequency and prognostic importance of pretreatment clinical characteristics in patients currently undergoing treatment for stage III non-small-cell lung cancer (NSCLC), data were collected on 378 receiving high-dose (120 mg/m2) cisplatin plus vinca alkaloid combination chemotherapy regimens since 1978. Variables analyzed included age, sex, weight loss, performance status, histologic subtype, presence extrathoracic metastases, number metastatic organ sites, liver, bone, or brain involvement, prior radiation surgery, serum lactate dehydrogenase (LDH). The effect a major response to survival was also investigated. Using multivariable analyses, following found be associated with outcome: initial having status 80% 100% an increased objective rate survival; bone which adversely predictive elevated ...
elsevier.com
sci-hub.se 参考文章(19)
David R. Cox, Regression Models and Life-Tables Springer Series in Statistics. ,vol. 34, pp. 527- 541 ,(1992) , 10.1007/978-1-4612-4380-9_37
, E. Chaves, Toão Pessoa, O. Campobasso, J. Chrétien, L. Hochholzer, L. Kreyberg, M. J. Matthews, P. Mirejovsky, I. G. Olchovskaya, G. Riotton, R. M. E. Seal, K. Shanmugaratnam, Y. Shimosato, L. H. Sobin, H. Spencer, R. Yesner, L. Zettergren, L. Kreyberg, M. F. Amorim, H. Brandt, R. Camain, J. Delarue, H. Hamperl, L. Haranghy, E. Letterer, A.A. Liebow, J. R. McDonald, E. E. Pantangco, V. Ramalingswami, R.E.J. ten Seldam, A.I. Strukov, A.C. Thackray, J. G. Thomson, H. Torloni, E. A. Uehlinger, H. Ungar, Histological typing of lung tumours Tumori. ,vol. 67, pp. 253- 272 ,(1981) , 10.1177/030089168106700401
J C Ruckdeschel, D M Finkelstein, B A Mason, R H Creech, Chemotherapy for metastatic non-small-cell bronchogenic carcinoma: EST 2575, generation V--a randomized comparison of four cisplatin-containing regimens. Journal of Clinical Oncology. ,vol. 3, pp. 72- 79 ,(1985) , 10.1200/JCO.1985.3.1.72
Nathan Green, S. S. Kurohara, F. W. George, Cancer of the lung. An in-depth analysis of prognostic factors. Cancer. ,vol. 28, pp. 1229- 1233 ,(1971) , 10.1002/1097-0142(1971)28:5<1229::AID-CNCR2820280521>3.0.CO;2-A
R Peto, M C Pike, P Armitage, N E Breslow, D R Cox, S V Howard, N Mantel, K McPherson, J Peto, P G Smith, Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. British Journal of Cancer. ,vol. 35, pp. 1- 39 ,(1977) , 10.1038/BJC.1977.1
Victor J. Lanzotti, David R. Thomas, Liam E. Boyle, Terry L. Smith, Edmund A. Gehan, Melvin L. Samuels, Survival with inoperable lung cancer.An integration of prognostic variables based on simple clinical criteria Cancer. ,vol. 39, pp. 303- 313 ,(1977) , 10.1002/1097-0142(197701)39:1<303::AID-CNCR2820390147>3.0.CO;2-U
RICHARD J. GRALLA, Cisplatin and Vindesine Combination Chemotherapy for Advanced Carcinoma of the Lung: A Randomized Trial Investigating Two Dosage Schedules Annals of Internal Medicine. ,vol. 95, pp. 414- 420 ,(1981) , 10.7326/0003-4819-95-4-414
Robert T. Eagan, Thomas R. Fleming, Vicki Schoonover, Evaluation of response criteria in advanced lung cancer Cancer. ,vol. 44, pp. 1125- 1128 ,(1979) , 10.1002/1097-0142(197909)44:3<1125::AID-CNCR2820440348>3.0.CO;2-4
Prognostic Factors for Survival in Patients With Inoperable Lung Cancer Journal of the National Cancer Institute. ,vol. 65, pp. 25- 32 ,(1980) , 10.1093/JNCI/65.1.25
J R Anderson, K C Cain, R D Gelber, Analysis of survival by tumor response. Journal of Clinical Oncology. ,vol. 1, pp. 710- 719 ,(1983) , 10.1200/JCO.1983.1.11.710